101 related articles for article (PubMed ID: 18398806)
21. New insights into understanding cardiometabolic risk. Introduction.
Fonarow GC; Watson KE
Rev Cardiovasc Med; 2007; 8 Suppl 4():S1-2. PubMed ID: 17934389
[No Abstract] [Full Text] [Related]
22. The importance of treating cardiometabolic risk factors in patients with type 2 diabetes.
Barnett AH
Diab Vasc Dis Res; 2008 Mar; 5(1):9-14. PubMed ID: 18398806
[TBL] [Abstract][Full Text] [Related]
23. The progression of cardiovascular risk to cardiovascular disease.
Rosin BL
Rev Cardiovasc Med; 2007; 8 Suppl 4():S3-8. PubMed ID: 17934392
[TBL] [Abstract][Full Text] [Related]
24. Abdominal adiposity and cardiometabolic risk: do we have all the answers?
Haffner SM
Am J Med; 2007 Sep; 120(9 Suppl 1):S10-6; discussion S16-7. PubMed ID: 17720354
[TBL] [Abstract][Full Text] [Related]
25. Adipokines--targeting a root cause of cardiometabolic risk.
Bakhai A
QJM; 2008 Oct; 101(10):767-76. PubMed ID: 18550581
[TBL] [Abstract][Full Text] [Related]
26. The importance of treating multiple cardiometabolic risk factors in patients with Type 2 diabetes.
Mikhailidis DP; Press M
Expert Opin Pharmacother; 2007 Dec; 8(17):3009-20. PubMed ID: 18001259
[TBL] [Abstract][Full Text] [Related]
27. Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk.
Després JP; Lemieux I; Bergeron J; Pibarot P; Mathieu P; Larose E; Rodés-Cabau J; Bertrand OF; Poirier P
Arterioscler Thromb Vasc Biol; 2008 Jun; 28(6):1039-49. PubMed ID: 18356555
[TBL] [Abstract][Full Text] [Related]
28. The endocannabinoid system and cardiometabolic risk.
Szmitko PE; Verma S
Atherosclerosis; 2008 Aug; 199(2):248-56. PubMed ID: 18440538
[TBL] [Abstract][Full Text] [Related]
29. Weight management for type 2 diabetes mellitus: global cardiovascular risk reduction.
Lee M; Aronne LJ
Am J Cardiol; 2007 Feb; 99(4A):68B-79B. PubMed ID: 17307059
[TBL] [Abstract][Full Text] [Related]
30. Type 2 diabetes and cardiovascular disease: getting to the fat of the matter.
Goralski KB; Sinal CJ
Can J Physiol Pharmacol; 2007 Jan; 85(1):113-32. PubMed ID: 17487251
[TBL] [Abstract][Full Text] [Related]
31. Challenges and strategies in managing cardiometabolic risk.
Repas TB
J Am Osteopath Assoc; 2007 Apr; 107(4 Suppl 2):S4-11. PubMed ID: 17784529
[TBL] [Abstract][Full Text] [Related]
32. [From the metabolic syndrome to the concept of global cardiometabolic risk].
Nádas J; Jermendy G
Orv Hetil; 2009 May; 150(18):821-9. PubMed ID: 19383573
[TBL] [Abstract][Full Text] [Related]
33. Advances in adipokines.
Sahin-Efe A; Katsikeris F; Mantzoros CS
Metabolism; 2012 Dec; 61(12):1659-65. PubMed ID: 23021039
[No Abstract] [Full Text] [Related]
34. Impact of visceral adipose tissue on liver metabolism. Part I: heterogeneity of adipose tissue and functional properties of visceral adipose tissue.
Lafontan M; Girard J
Diabetes Metab; 2008 Sep; 34(4 Pt 1):317-27. PubMed ID: 18550411
[TBL] [Abstract][Full Text] [Related]
35. Obesity, adipokines and metabolic syndrome in polycystic ovary syndrome.
Carmina E
Front Horm Res; 2013; 40():40-50. PubMed ID: 24002404
[TBL] [Abstract][Full Text] [Related]
36. Metabolic complications of obesity: inflated or inflamed?
Chandalia M; Abate N
J Diabetes Complications; 2007; 21(2):128-36. PubMed ID: 17331862
[TBL] [Abstract][Full Text] [Related]
37. Pathogenic potential of adipose tissue and metabolic consequences of adipocyte hypertrophy and increased visceral adiposity.
Bays HE; González-Campoy JM; Bray GA; Kitabchi AE; Bergman DA; Schorr AB; Rodbard HW; Henry RR
Expert Rev Cardiovasc Ther; 2008 Mar; 6(3):343-68. PubMed ID: 18327995
[TBL] [Abstract][Full Text] [Related]
38. The link between abdominal obesity, metabolic syndrome and cardiovascular disease.
Ritchie SA; Connell JM
Nutr Metab Cardiovasc Dis; 2007 May; 17(4):319-26. PubMed ID: 17110092
[TBL] [Abstract][Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
